A B S T R A C T
Rhabdomyolysis is one of the most concerning complications of antidyslipidemic drugs. Most patients with dyslipidemia take multiple medications. Our objective was to explore which two-drug combinations lead to a higher risk of rhabdomyolysis. We analyzed data from the Japanese Adverse Drug Event Report (JADER) database between April 2004 and September 2017. The primary outcome was the report of rhabdomyolysis. We assessed the risk of rhabdomyolysis for the two-drug concomitant use of antidyslipidemic drugs (statin, fibrate, and ezetimibe) with antihypertensive and antidiabetic medications. The Nor en and Gosho methods were used for detecting two-drug interactions. The JADER contained 468 292 records for patient characteristics, 2 973 172 drug information records, and 741 016 adverse reactions records. Rhabdomyolysis was reported in 5 017 patients. Concomitant use of pravastatin/fenofibrate, simvastatin/mefruside, fluvastatin/temocapril, bezafibrate/ temocapril, bezafibrate/spironolactone, bezafibrate/metoprolol, bezafibrate/losartan, fluvastatin/mitiglinide, or fenofibrate/glibenclamide was detected as the signal of rhabdomyolysis in this analysis. Combination therapy with the drugs listed above has the potential of drug-drug interactions that could result in rhabdomyolysis in patients with dyslipidemia.
I N T R O D U C T I O N
Dyslipidemia can lead to cardiovascular disease, and statin therapy is the first-line therapy for dyslipidemia that reduces the risk of cardiovascular morbidity and mortality [1] . However, some patients have residual cardiovascular risk despite optimal statin treatment [2] . Fibrates improve atherogenic dyslipidemia characterized by high triglyceride levels, low high-density lipoprotein cholesterol levels, or both and elevated concentrations of small dense low-density lipoprotein particles [3] . Ezetimibe also prevents cholesterol absorption in the gastrointestinal tract [4] .
Myotoxicity is the most important complication of most lipid-lowering medications including statins, fibrates, and niacin [4] . Muscular adverse events are usually mild and reversible; however, these events may be a prelude to rhabdomyolysis, a very rare but potentially serious and life-threatening clinical condition [5] . The risk factors for rhabdomyolysis in patients prescribed statins have been discussed and identified. Age is a wellknown risk factor for statin-induced rhabdomyolysis; female sex, and small body frame and frailty may be additional demographic risk factors [5] [6] [7] . Statin-related adverse effects are dose-related [5, 8] . Hydrophilic statins are likely less myotoxic than lipophilic statins, though no clinical evidence supports a direct association between the degree of lipophilicity and myotoxicity [5, 9] .
Drug-drug interactions (DDIs) are one of the exogenous risk factors of rhabdomyolysis [5] . Statins may cause rhabdomyolysis when used concurrently with fibrates. In particular, the risk is higher when statins are used with gemfibrozil compared to other fibrates such as fenofibrate [10] . The risk of myotoxicity increases in patients administered a statin with niacin [5, 11] . In contrast, the concomitant use of statins and ezetimibe unlikely increases the risk of muscle-related events [4, 5, 11] . However, isolated reports have described myopathy with the concurrent use of ezetimibe and atorvastatin, and increased creatine kinase levels with the concurrent use of ezetimibe and fluvastatin [11] . Bellosta and Corsini [12] recently provide a brilliant review of the potential statin DDIs. In a clinical trial, myopathy was not detected with the individual or combined administration of ezetimibe and fenofibrate [13] .
Several patients with dyslipidemia have other lifestyle-related diseases such as hypertension and diabetes mellitus. Consequently, they take multiple medications for these diseases. Statin-induced rhabdomyolysis has been reported with the concomitant use of calcium channel antagonists for hypertension, such as amlodipine, diltiazem, and verapamil, as they increase statin exposure [11] . The package insert of amlodipine and diltiazem in Japan has a warning that concomitant therapy using simvastatin medications may increase the risk of rhabdomyolysis. With the combination of diltiazem and simvastatin, the dose of simvastatin should not exceed 20 mg daily (UK advice) or 10 mg daily (US advise) [11] . The package insert of some angiotensin II receptor blockers, metformin, pioglitazone, and some dipeptidyl peptidase-IV (DPP4) inhibitors in Japan has a warning that these medications may cause rhabdomyolysis as a critical adverse drug reaction (ADR). Buttar et al. [14] also report the occurrence of rhabdomyolysis following association of statins and DPP4 inhibitors.
Spontaneous reporting systems are crucial in postmarketing drug safety surveillance. They are commonly used to detect suspected ADRs and generate hypotheses of new ADRs in real-world settings. Regulatory authorities have been preparing databases for spontaneous reporting systems since the 1960s. Some researchers have used the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database to investigate the DDIs between statins and other drugs that underlie a higher risk of rhabdomyolysis [15, 16] . Expectedly, the signal of rhabdomyolysis was detected after the concomitant use of statin and fibrate. Statin-induced rhabdomyolysis has also been reported with the concomitant use of mibefradil, cyclosporine, macrolide antibiotics, warfarin, digoxin, and azole antifungals [16] . However, in previous studies, the risk of rhabdomyolysis was not evaluated when other antidyslipidemic medications, such as fibrate and ezetimibe, were concurrently used with antidiabetic and antihypertensive medications. In this study, we assessed the risk of rhabdomyolysis associated with the two-drug concomitant use of antidyslipidemic drugs (statin, fibrate, ezetimibe) with antihypertensive and antidiabetic medications by using the Japanese Adverse Drug Event Report (JADER) database and statistical methods for detecting two-drug interactions.
M A T E R I A L S A N D M E T H O D S

Data source
The JADER database contains information on suspected ADR incidents spontaneously reported by pharmaceutical companies and hospitals in Japan. The database is managed by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA); it was set up in 2004 and is updated quarterly [17] . The structure of the database complies with the international safety reporting guidelines (International Conference on Harmonization E2B). It comprises four data sets as follows: patient characteristics [e.g., sex, categorized age, and categorized body weight], drug information (e.g., drug name, route of drug administration, and amount of drug), reactions/ events (e.g., ADR name, nature of ADR, and case outcome), and medical history (e.g., primary disease). We downloaded the JADER database from the PMDA website [17] and analyzed data from the database between April 2004 and September 2017. A total of 468 292 patient characteristics records, 2 973 172 drug information records, and 741 016 reactions/events were used in this analysis.
Definition of outcome and medications
The primary outcome of the analysis was rhabdomyolysis, which is defined in the Medical Dictionary for Regulatory Activities (version 20) in Japanese with 'rhabdomyolysis' as the preferred term. The antidyslipidemic, antihypertensive, and antidiabetic drugs included in this analysis are listed in Tables S1-S3. Drug combinations, such as atorvastatin-amlodipine, atorvastatinezetimibe, and valsartan-amlodipine, are separately included in the analysis data set. When two target drugs were reported for a patient, it was considered that the two drugs were used in combination.
Statistical analysis
First, we assessed the relationship between rhabdomyolysis incidence and each antidyslipidemic drug using traditional approaches, that is, reporting odds ratio (ROR) [18] and Bayesian confidence propagation neural network method based on an information component (IC) [19] for signal detection. When the lower limit of 95% confidence interval (CI) of the ROR exceeds one, this implies that a signal is generated for the apparent association between a drug and rhabdomyolysis [19] . When the lower limit of 95% CI of the IC exceeds zero, a potential signal is generated for the association between a drug and rhabdomyolysis.
In order to detect DDIs resulting in rhabdomyolysis associated with the concomitant use of two drugs, we analyzed the data set using the methods proposed by Nor en et al. [20] and Gosho et al. [21] . The two methods quantitatively measure the discrepancy between the observed and expected number of adverse events after administration of the combination of two drugs. In this analysis, two drugs, one being an antidyslipidemic drug and the other being an antidyslipidemic drug of another class or an antihypertensive or antidiabetic drug, were analyzed ( Table I) . n 111 denotes the number of reports on rhabdomyolysis listing both drugs D 1 and D 2 . The number of ADR reports excluding rhabdomyolysis and the total number of reports are shown in Table I . Except for n 111 ¼ 0, the following two-drug combinations were evaluated: a statin and another antidyslipidemic drug, a statin and an antihypertensive drug, a statin and an antidiabetic drug, a fibrate and another antidyslipidemic drug, a fibrate and an antihypertensive drug, a fibrate and an antidiabetic drug, ezetimibe and another antidyslipidemic drug, ezetimibe and an antihypertensive drug, and ezetimibe and an antidiabetic drug.
Nor en et al. have developed a criterion X 025 for detecting DDIs from using two drugs. X 025 [ 0 is used as a threshold to screen for signals when undergoing treatment with a combination of two drugs [20] . Gosho et al. have proposed another statistical criterion v based on the chi-square statistics with the Yates' correction to detect DDIs when using two drugs simultaneously. v [ 2 is set as a threshold for screening adverse DDIs [21] . Missing data for all variables were not imputed. All analyses were performed using the SAS software version 9.4 (SAS Institute, Cary, NC) and using the data sets generated in our previous study [22] .
R E S U L T S
The patient characteristics of the JADER analysis population are presented in Table II . This table is also shown in the previous study [22] . The percentage of patients with the reported indications of hypertension, dyslipidemia, and diabetes was 20.8, 8.4, and 13.5%, respectively.
Rhabdomyolysis was reported in 5 036 events occurring in 5 017 patients. The calculated ROR and IC values were used to detect rhabdomyolysis following the use of the antidyslipidemic drugs in Table S1 . The ROR and IC criteria indicated an increased risk of rhabdomyolysis associated with the use of the antidyslipidemic drugs listed in Table III . The lower limit of the 95% CI of the ROR for the drugs was in the following order: bezafibrate > atorvastatin > simvastatin > rosuvastatin > ezetimibe (Table III) , whereas the lower limit for the IC was in the following order: bezafibrate > simvastatin > atorvastatin > rosuvastatin > ezetimibe. There was no signal of rhabdomyolysis when clofibrate, omega-3 fatty acid, niceritrol, gamma oryzanol, or cholestyramine was used ( Table III) . The analysis results from single use of antihypertensive drugs and antidiabetic drugs are shown in Tables S4 and S5, respectively. Drug-drug interactions associated with concomitant drug use and resulting in rhabdomyolysis were analyzed using X 025 and v. A total of 1 277 drug combinations were assessed in this analysis. All results, except for n 111 ¼ 0, are shown in Table S6 . With 462 drug combinations, n 111 was ≥ 1, and with 264 drug combinations, n 111 was ≥ 3. Table IV lists the drug combinations that were associated with rhabdomyolysis detected using X 025 or v. Eleven combinations were detected in this analysis. Rhabdomyolysis resulting from the concomitant use of any statin/ezetimibe and any fibrate/ezetimibe was not detected (Table S6) . When statin, fibrate, or ezetimibe and antihypertensive drugs were concurrently used, rhabdomyolysis was detected for six-drug combinations. Concomitant use of fluvastatin and temocapril produced the highest X 025 value. Concomitant use of simvastatin and mefruside also produced the highest v value followed by bezafibrate and losartan combination. Furthermore, for the statin, fibrate, or ezetimibe and antidiabetic drug combinations, rhabdomyolysis was detected for four-drug combinations. Concomitant use of fluvastatin and mitiglinide produced the highest X 025 and v values. Although rhabdomyolysis following the concomitant use of fluvastatin/repaglinide and pravastatin/glyclopyramide was detected using the v criterion, the number of reports of rhabdomyolysis, n 111 , was quite small (=1).
D I S C U S S I O N
Rhabdomyolysis is one of the most important ADRs to antidyslipidemic drugs, especially fibrate and statin. In the present study, the ROR and IC values and their lower limits of the 95% CI for bezafibrate were relatively higher than the respective values for other fibrates. The findings of Wu et al. [23] support these results. Among fibrates, gemfibrozil treatment was most commonly associated with rhabdomyolysis, followed by bezafibrate, fenofibrate, ciprofibrate, and clofibrate [23] . However, gemfibrozil and ciprofibrate are not approved in Japan. The risk of rhabdomyolysis was the lowest for pravastatin among the six statins used in this analysis (Table III) . Pravastatin is one of the hydrophilic statins, which are less likely to enter the muscle tissue, theoretically reducing the risk of muscle injury, although egress from cells depends on statin solubility and can cause DDIs [24] . In addition, pravastatin is metabolized through several pathways and is renally excreted owing to its hydrophilic nature [5] . This theoretically renders it safer than other drugs as far as its potential for DDIs is concerned [5] .
In contrast, our analysis showed that the signal of rhabdomyolysis was detected after the concomitant use of pravastatin/fenofibrate. Concomitant administration of pravastatin and fenofibrate did not affect the pharmacokinetics of either pravastatin or fenofibrate in healthy volunteers, although the concentration of a metabolite of pravastatin was moderately increased [25] . However, gemfibrozil increases plasma pravastatin concentration and reduces pravastatin renal clearance [26] . Other combination statin-fibrate therapies did not increase the risk of rhabdomyolysis in our analysis. This is because rhabdomyolysis is a wellrecognized complication of the combination of statins and fibrates, and clinicians pay attention to the risk of myotoxicity with statin-fibrate combination therapy in practice.
When statin, fibrate, or ezetimibe and antihypertensive drugs were concurrently used, rhabdomyolysis was detected for six-drug combinations ( Table IV) . One of the combinations was simvastatin/mefruside. Mefruside is a diuretic, and hypokalemia is the most frequent ADR of diuretics. A frequently undiagnosed serious complication of hypokalemia is rhabdomyolysis [27] . A case of rhabdomyolysis due to diuretic treatment was reported [27] . The pharmacological reasons for the occurrence of DDIs with fluvastatin/temocapril are unknown. It is noteworthy that the ROR and IC values and their lower limits of 95% CI for temocapril are third largest following those for delapril and benazepril, and the number of reports of rhabdomyolysis for temocapril is relatively high among the angiotensin- converting enzyme inhibitors (ACEi) studied (Table S4) . Analysis of the concomitant use of fibrates and antihypertensive drugs indicated that rhabdomyolysis occurred with the following four combinations: bezafibrate/temocapril, bezafibrate/spironolactone, bezafibrate/metoprolol, and bezafibrate/losartan. This result led to a new hypothesis that the four combinations pose a risk of rhabdomyolysis. In contrast, DDIs resulting in rhabdomyolysis after the concomitant use of fenofibrate and antihypertensive drugs were not observed in this analysis. The use of fenofibrate would be safer than bezafibrate use for the management of dyslipidemia with hypertension. The findings of Wu et al. [23] support this result. When a statin, fibrate, or ezetimibe and antidiabetic drugs were concurrently used, DDIs resulting in rhabdomyolysis with fluvastatin/mitiglinide and fenofibrate/ glibenclamide were identified based on both X 025 and v. Regarding the former, co-administration of simvastatin and repaglinide, a cytochrome P450 (CYP) 3A4 enzyme substrate, slightly increased the mean plasma concentrations of repaglinide, although the concentrations of simvastatin were not measured [28] . The risks associated with the concomitant use of statins and glinides are not included as a warning in the package inserts of either drug in Japan. Moreover, glibenclamide is mainly metabolized by CYP 3A4, CYP 2C9, and 2C19 [29] . Fenofibrate could increase the plasma concentrations of glibenclamide because fenofibrate moderately inhibits CYP 2C9 [29] . However, it is unclear whether the plasma concentrations of fenofibrate increase when glibenclamide and fenofibrate are co-administered. The package insert of fenofibrate also includes a warning for the risk of hypoglycemia but not rhabdomyolysis, resulting from the concomitant use of fenofibrate and glibenclamide. There were some limitations of this study. First, in DDI analysis, missing information for one of the two drugs yielded overestimated relative reporting rates of ADRs after monotherapy [20] . This is a critical problem in the evaluation of adverse DDIs. This information gap leads to under-reporting of n 111 and overreporting of n 101 or n 011 (Table I) . Thus, the measures for DDI detection are underestimated. Second, this study did not consider the risk of rhabdomyolysis with three or more drugs. Moreover, X 025 and v cannot be used to detect DDIs with three or more drugs. Patients with dyslipidemia who are administered medications are likely to be exposed to polypharmacy. These limitations are pointed out in the previous study [22] . Third, the results from the JADER analysis were based on the data from Japanese patients only. The generalizability of results from the analysis should be considered in future studies. Finally, age is a risk factor for rhabdomyolysis [5] [6] [7] . The increased risk of developing rhabdomyolysis in elderly patients may be due to increased sensitivity to therapy. Subgroup analysis in elderly patients may be useful for assessing rhabdomyolysis as a DDI consequence; however, the analysis will not provide valid results with sufficient precision because of the small number of reports with concomitant use. Although we were unable to reach definite conclusions because of the above-mentioned limitations, the results of our analysis generate a new hypothesis for rhabdomyolysis as a possibility of a potential DDI consequence resulting from the concomitant use of antidyslipidemic drugs with antihypertensive and antidiabetic medications.
C O N C L U S I O N
The concomitant use of pravastatin/fenofibrate, simvastatin/mefruside, fluvastatin/temocapril, bezafibrate/temocapril, bezafibrate/spironolactone, bezafibrate/metoprolol, bezafibrate/losartan, fluvastatin/mitiglinide, or fenofibrate/glibenclamide was detected to be at risk of rhabdomyolysis in the JADER analysis. However, due to various limitations (missing information on concomitant drug use, combination use of three or more drugs, and restricted population), these results must be confirmed by additional analyses.
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